Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term phase-ii. Found 40 abstracts

no pagination
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Oct;10(10):1211-9.   PMCID: not NIH funded
Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong CY, Hittelman WN, Wen XX, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity. Molecular Cancer Therapeutics. 2012 Jan;11(1):143-53.
Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Annals of Oncology. 2012 May;23(5):1335-40.   PMCID: PMC3493136 [Available on 2013/5/1]
Gillet JP, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research. 2012 Jun;18(11):3197-206.   PMCID: PMC3376649
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May;119(20):4597-607.   PMCID: not NIH funded
Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM. Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells. Molecular Cancer Therapeutics. 2012 Jul;11(7):1510-7.   PMCID: PMC 3491642
Martins RG, D'Amico TA, Loo BW, Pinder-Schenck M, Borghaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE. The Management of Patients With Stage IIIA Non-Small Cell Lung Cancer With N2 Mediastinal Node Involvement. Journal of the National Comprehensive Cancer Network. 2012 May;10(5):599-613.   PMCID: not NIH funded
Patson B, Cohen RB, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology. 2012 Feb;8(2):259-70.   PMCID: not NIH funded
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SR, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Jun;10(6):703-13.   PMCID: not NIH funded
Vadakara J, Pro B. Targeting CD30 in Anaplastic Large Cell Lymphoma. Current Hematologic Malignancy Reports. 2012 Dec;7(4):285-91.   PMCID: Not NIH fund
Adams SF, Marsh EB, Elmasri W, Halberstadt S, VanDecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC, Belsadron G, Biochimie V P. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecologic Oncology. 2011 Dec;123(3):486-91.   PMCID: PMC3260049
Dawood S, Cristofanilli M. Inflammatory Breast Cancer: What Progress Have We Made?. Oncology-New York. 2011 Mar;25(3):264-73.   PMCID: not NIH funded
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011 Mar;22(3):515-23.   PMCID: PMC3105293
Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, Berger AC. DO ELDERLY PATIENTS EXPERIENCE INCREASED PERIOPERATIVE OR POSTOPERATIVE MORBIDITY OR MORTALITY WHEN GIVEN NEOADJUVANT CHEMORADIATION BEFORE ESOPHAGECTOMY?. International Journal of Radiation Oncology Biology Physics. 2011 Aug;80(5):1372-6.   PMCID: not NIH funded
Gupta S, Engstrom PF, Cohen SJ. Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer. 2011 Dec;10(4):298-309.   PMCID: NIHMS329029
Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology. 2011 Oct;16(5):596-600.   PMCID: *
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. Journal of Clinical Oncology. 2011 Mar;29(7):934-43.   PMCID: PMC3068065
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology. 2011 Jul;29(19):2660-6.   PMCID: not NIH funded
Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Annals of Oncology. 2011 Nov;22(11):2523-9.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term phase-ii

phase-ii survival carcinoma chemotherapy antitumor-activity therapy cancer follow-up pancreatic endocrine tumors trial her2 induction chemotherapy monoclonal-antibody gastrointestinal stromal tumors growth-factor trastuzumab imatinib mesylate endothelial growth-factor tumors stem-cell transplantation in-vitro management neoadjuvant chemotherapy dose neu-overexpressing metastatic breast 1989 audhary vk-nature-v339-p394 non-hodgkins-lymphoma interferon-alpha in-vivo pd 0332991 BRCA mutations Esophagectomy protein expression adjuvant chemotherapy multikinase squamous-cell carcinoma guidelines 2008 orge s-j clin oncol-v26 receptor synchronous occurrence cell death gemcitabine registry animal toxicity CD30 Anaplastic large cell lymphoma-SGN-35-Brentuximab-Vedotin-MMAE-T-cell lymphoma ribosome-inactivating proteins long-term survival progression 1994 audhry a-anticancer research-v14-p2085 concurrent chemotherapy macroglobulinemia clinical-trial microarray chemoradiotherapy breast-cancer Circulating tumor cell contrast-enhanced mri stage-iii 2002 llo sp-biol chem-v383-p69 emission-tomography diastolic blood-pressure somatostatin sgn-30 igm Elderly 1993 wler wc-annals of thoracic surgery-v55-p986 colorectal-cancer malignant carcinoid-syndrome plus VEGF solid tumors pathogenesis brentuximab vedotin sgn-35 expression profiles rhoc-gtpase topotecan aneusomy human angiogenin neoadjuvant therapy hematologic malignancies 2003 silva cm-pathol oncol res-v9-p13 platinum dexamethasone pathway 1992 audhry a-cancer research-v52-p1006 gene amplification metastatic Targeted therapy pancreaticoduodenectomy Neuroendocrine tumors Ovarian cancer weekly bortezomib 1993 audhry a-acta oncologica-v32-p107 vegf metastatic carcinoid-tumors surgery dependent kinase inhibitor Chemotherapy 2007 orge s-j clin oncol-v25 Neoadjuvant therapy gastroesophageal junction cyclin d1 cancer statistics angiogenesis inhibitor glioblastoma oophorectomy radiation-therapy progression-free survival nucleotide polymorphism analysis positron-emission-tomography tyrosine kinase inhibitor signal-transduction pathway 2nd international workshop neoplasms c-kit 1995 ristofori g-molecular endocrinology-v9-p1760 anti-cd30 kit mutations Polysomy recombinant immunotoxin inflammatory breast cancer resistance 2008 matteo d-p am soc clin oncol-v26 angiogenesis tyrosine kinase inhibitors immunogenicity solid somatostatin analog Breast neoplasm t-lymphocytes doxorubicin interstitial-cells vascular endothelial growth factor growth-factor receptor margin status consensus panel recommendations cell-death Radiation therapy sorafenib 1989 sner mc-archives of surgery-v124-p191 scid mice ret protooncogene mutations cancer-therapy 1995 boer cj-oncogene-v10-p1833 immunoglobulin-m AG-013736 helical ct centrocytic lymphoma bnip3
Last updated on Saturday, July 04, 2020